Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

303 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study.
LoRusso P, Yamamoto N, Patel MR, Laurie SA, Bauer TM, Geng J, Davenport T, Teufel M, Li J, Lahmar M, Gounder MM. LoRusso P, et al. Among authors: teufel m. Cancer Discov. 2023 Aug 4;13(8):1802-1813. doi: 10.1158/2159-8290.CD-23-0153. Cancer Discov. 2023. PMID: 37269344 Free PMC article. Clinical Trial.
Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies.
Geoerger B, Morland B, Jiménez I, Frappaz D, Pearson ADJ, Vassal G, Maeda P, Kincaide J, Mueller U, Schlief S, Teufel M, Ploeger BA, Cleton A, Agostinho AC, Marshall LV. Geoerger B, et al. Among authors: teufel m. Eur J Cancer. 2021 Aug;153:142-152. doi: 10.1016/j.ejca.2021.05.023. Epub 2021 Jun 20. Eur J Cancer. 2021. PMID: 34157616 Free article. Clinical Trial.
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.
Van Laethem JL, Riess H, Jassem J, Haas M, Martens UM, Weekes C, Peeters M, Ross P, Bridgewater J, Melichar B, Cascinu S, Saramak P, Michl P, Van Brummelen D, Zaniboni A, Schmiegel W, Dueland S, Giurescu M, Garosi VL, Roth K, Schulz A, Seidel H, Rajagopalan P, Teufel M, Childs BH. Van Laethem JL, et al. Among authors: teufel m. Target Oncol. 2017 Feb;12(1):97-109. doi: 10.1007/s11523-016-0469-y. Target Oncol. 2017. PMID: 27975152 Clinical Trial.
Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma.
Lim HY, Merle P, Weiss KH, Yau T, Ross P, Mazzaferro V, Blanc JF, Ma YT, Yen CJ, Kocsis J, Choo SP, Sukeepaisarnjaroen W, Gérolami R, Dufour JF, Gane EJ, Ryoo BY, Peck-Radosavljevic M, Dao T, Yeo W, Lamlertthon W, Thongsawat S, Teufel M, Roth K, Reis D, Childs BH, Krissel H, Llovet JM. Lim HY, et al. Among authors: teufel m. Clin Cancer Res. 2018 Oct 1;24(19):4650-4661. doi: 10.1158/1078-0432.CCR-17-3588. Epub 2018 Jun 27. Clin Cancer Res. 2018. PMID: 29950351 Free article. Clinical Trial.
Neurofeedback Reduces P300 Amplitudes to Intensely Emotive Pictures in Depressed Cancer Patients.
Krawutschke M, Teufel M, Schmidt K, Pasche S, Schweig T, Bialek A, Kowalski A, Tewes M, Schuler M, Schadendorf D, Scherbaum N, Skoda EM, Fink M, Müller BW. Krawutschke M, et al. Among authors: teufel m. Clin EEG Neurosci. 2024 Oct 21:15500594241287961. doi: 10.1177/15500594241287961. Online ahead of print. Clin EEG Neurosci. 2024. PMID: 39431413 Free article.
Differential effects of mindfulness treatment and mobile neurofeedback on event-related potentials in early posterior negativity in cancer patients: a clinical-experimental parallel group design.
Fink M, Schmidt K, Kowalski A, Pasche S, Albrot C, Krawutschke M, Schweig T, Tewes M, Skoda EM, Teufel M, Müller BW. Fink M, et al. Among authors: teufel m. Front Psychol. 2024 Oct 1;15:1395032. doi: 10.3389/fpsyg.2024.1395032. eCollection 2024. Front Psychol. 2024. PMID: 39411559 Free PMC article.
303 results